Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
GMED
Strong BuyUnloved QualityFLAGGlobus Medical, Inc. · Healthcare · United States · $11.1B · Avg Vol: $98M/d
Globus Medical has strong quality at Q80 but V54 and M54 keep it off the all-above-60 route, and the only insider activity is a small sale so nothing corroborates. Spine and robotics surgical devices after the NuVasive integration.
COMPANY DESCRIPTION
Globus Medical, Inc. is a medical device company focused on musculoskeletal health, designing, developing, and marketing implants, instruments, and robotic navigation systems for spinal and orthopedic surgeries. Known for rapid innovation and strong R&D, it offers a comprehensive portfolio of solutions, including advanced robotic assistance systems. Its focus on challenging surgical cases and proprietary technologies provides a competitive edge in a specialized market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0B | 1.6B | 2.5B | 2.9B | 42.2% | 3.1B | 3.2B | 3.4B | 7.4% |
| EPS | 1.89 | 1.09 | 0.76 | 3.98 | 28.2% | 3.91 | 5.00 | 5.40 | 16.5% |
| Shares | 100.2M | 136.3M | 137.4M | 112.6M | +12.4% | 111.8M | — | — | — |
| Debt | 6.0M | 520.4M | 537.2M | 118.7M | 170.3% | 111.9M | — | — | — |
| Equity | 1.8B | 4.0B | 4.2B | 4.6B | 35.3% | — | — | — | — |
| Op CF | 178.5M | 243.5M | 520.6M | 753.4M | 61.6% | 910.4M | — | — | — |
| Inv CF | -110.4M | 303.0M | -176.1M | -355.0M | — | — | — | — | — |
| Fin CF | -110.0M | -231.8M | -27.7M | -679.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GMED are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GMED | Globus Medical, Inc.(you) | $11.1B | 92 | Strong Buy |
| BIO-B | Bio-Rad Laboratories, Inc. | $8.3B | 78 | Buy |
| ZBH | Zimmer Biomet Holdings, Inc. | $19.2B | 83 | Strong Buy |
| HAE | Haemonetics Corporation | $4.7B | 86 | Strong Buy |
| STE | STERIS plc | $22.8B | 76 | Buy |
| DXCM | DexCom, Inc. | $34.3B | 83 | Strong Buy |
| UFPT | UFP Technologies, Inc. | $2.3B | 80 | Strong Buy |
| ITGR | Integer Holdings Corporation | $4.3B | 68 | Buy |
| PEN | Penumbra, Inc. | $12.7B | 51 | Hold |
| CNMD | CONMED Corporation | $1.5B | 87 | Strong Buy |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%